Abstracts tagged "ANCA"

Abstract Number: 1573 • ACR Convergence 2022
Von – Willebrand Factor, a Possible Marker for Disease Activity in Vasculitis
Jomana mazareeb¹, shiri keret¹, Abid Awisat¹, Itzhak Rosner², Michel Rozenbaum³, Lisa Kaly¹, Gleb Slobodin¹ and Doron Rimar¹, ¹Bnai Zion Medical Center, Haifa, Israel, ²Bnai Zion Medical Center/Technion, Haifa, Israel, ³Bnei Zion Medical Center, Hertzeliya, Israel
Background/Purpose: Vasculitis is an inflammation of blood vessels. While in many cases markers of inflammation as c- reactive protein (CRP) or erythrocytes sedimentation rate (ESR)…
Abstract Number: 0438 • ACR Convergence 2022
Characterization of Interstitial Lung Disease in the Presence of Antineutrophil Cytoplasmic Antibodies
Khai-Tuan Andrew Bui¹, Rachel Richard², Ariane Drouin³, Nader Toban¹, Marianne Levesque⁴, Rosalie-Selene Meunier⁵, Carolyn Ross⁶ and Jean-Paul Makhzoum³, ¹Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montréal, QC, Canada, ²Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Laval, QC, Canada, ³Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montréal, QC, Canada, ⁴Division of Respirology, Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montréal, QC, Canada, ⁵Hopital Sacre-Coeur, Universite de Montreal, Montréal, QC, Canada, ⁶University of Montreal, Montréal, QC, Canada
Background/Purpose: Various pulmonary manifestations may occur in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). ANCA-related interstitial lung disease (ILD) has recently been described in…
Abstract Number: 1688 • ACR Convergence 2022
Biomechanical Phenotype of Circulating Neutrophils Is Altered in ANCA Associated Vasculitis
Noelle Pisacano¹, Stephen P. McAdoo¹, Jochen Guck², Charles D. Pusey¹, Edwin R. Chilvers¹, Andrew S. Cowburn¹, Katharine M. Lodge¹ and Maria F. Prendecki¹, ¹Imperial College London, London, United Kingdom, ²Max Planck Institute, Erlangen, Germany
Background/Purpose: Real Time-Deformability Cytometry (RT-DC) is a novel technique able to identify morpho-rheological characteristics of individual cells such as size, deformability, and elasticity using only…
Abstract Number: 0439 • ACR Convergence 2022
Clinical Characteristics of Patients with ANCA-Associated Vasculitis with and Without Alpha-1 Antitrypsin Deficiency Alleles
Lynn Fussner¹, David Cuthbertson², Peter Grayson³, David Jayne⁴, Carol McAlear⁵, Michael Walsh⁶, Katherine Siminovitch⁷, Ulrich Specks⁸ and Peter Merkel⁹, ¹The Ohio State University, Columbus, OH, ²University of South Florida, Tampa, FL, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴University of Cambridge, Cambridge, United Kingdom, ⁵Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁶McMaster University, Hamilton, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸Mayo Clinic, Rochester, MN, ⁹University of Pennsylvania, Philadelphia, PA
Background/Purpose: There are multiple reasons to suspect that alpha-1 antitrypsin (A1AT) genotype impacts disease characteristics in ANCA-associated vasculitis (AAV). A1AT serves as the predominant endogenous…
Abstract Number: 1928 • ACR Convergence 2022
Idiopathic Pulmonary Capillaritis Within the Spectrum of Pediatric Diffuse Alveolar Hemorrhage
Angela Chun¹, Tiphanie vogel¹, Andrea Ramirez¹, Marietta De Guzman², Eyal Muscal¹ and Manuel Silva-Carmona³, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a life-threatening syndrome with bleeding from the pulmonary microvasculature. It is classified as pulmonary capillaritis if histology shows neutrophilic…
Abstract Number: 0442 • ACR Convergence 2022
Induction Therapy Patterns for Severe ANCA-associated Vasculitis Differ Based on Physician Specialty, Expertise, and Practice Setting: An International Survey
Lilian Xu¹, Faten Aqeel¹, Ojaswi Tomar², Tingting Li² and Duvuru Geetha¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Washington University in St. Louis School of Medicine, St. Louis, MO
Background/Purpose: Therapies for ANCA-associated vasculitis (AAV) have evolved over the last 3 decades. In light of new data on plasma exchange (PLEX) and glucocorticoid (GC)…
Abstract Number: 1948 • ACR Convergence 2022
Clinical Characteristics and Outcomes of Pediatric ANCA-Associated Vasculitis Patients: Single-Center Inception Cohort
Hyun Ho Lee¹, Lauren Blazek² and Eveline Wu³, ¹The University of North Carolina Chapel Hill, Chapel Hill, NC, ²UNC Kidney Center, The University of North Carolina Chapel Hill, Chapel Hill, NC, ³University of North Carolina, Chapel Hill, NC
Background/Purpose: ANCA associated vasculitis (AAV) is a chronic autoimmune disorder characterized by ANCA production and small vessel inflammation and necrosis. ANCA autoantigen targets include myeloperoxidase…
Abstract Number: 0443 • ACR Convergence 2022
Prognosis of Non-PR3 ANCA-Associated Vasculitis with Glomerulonephritis
Aurélien Chepy¹, Hélène Béhal², Alexandre Karras³, Xavier Puéchal⁴, Benjamin Terrier⁴, David Jayne⁵, Thomas Quéméneur⁶ and Mary-Jane Guerry⁷, ¹CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, ²University of Lille, CHU Lille, ULR 2694 - METRICS: Évaluation des Technologies de Santé et des Pratiques Médicales, Lille, France, ³HEGP, Paris, France, ⁴National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶Valenciennes Hospital, Valenciennes, France, ⁷Department of Nephrology, Centre Hospitalier de Valenciennes, Valenciennes., Valenciennes, France
Background/Purpose: Immunosuppressive treatments have improved the prognosis of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV), transforming these formerly fatal diseases into chronic conditions, with periods of…
Abstract Number: 0450 • ACR Convergence 2022
Incidence of Solid and Hematologic Tumors in Patients with ANCA: A 10-year Retrospective Cohort Study
Enrico Brunetta¹, Giacomo Ramponi², marco folci², Maria De Santis³, Giacomo Maria Guidelli¹, Angela Ceribelli⁴, Nicoletta Luciano¹, Marta Caprioli⁵, Arianna Sonaglia¹ and Carlo Selmi⁶, ¹IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano, Italy, ²IRCCS Humanitas Research Hospital, Internal Medicine, Rozzano, Italy, ³Humanitas University, IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Pieve Emanuele, Italy, ⁴Humanitas Research Hospital, Humanitas University, Rozzano (MI) Italy, Borgo San Giacomo, Italy, ⁵IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Pavia, Italy, ⁶IRCCS Humanitas Research Hospital, Humanitas University, Rozzano (MI), Italy, Rozzano, Italy
Background/Purpose: Serum antineutrophil cytoplasmic antibodies (ANCA) are significantly associated with the development of ANCA-associated vasculitides (AAV) but may also be detected in patients with other…
Abstract Number: 0457 • ACR Convergence 2022
A Systematic Literature Review Informing the 2022 Update of the EULAR Recommendations for the Management of ANCA-associated Vasculitis
Jan Schirmer¹, Beatriz Sanchez-Alamo², Sara Monti³, Bernhard Hellmich⁴, David Jayne⁵ and Gunnar Tomasson⁶, ¹University Medical Center Schleswig-Holstein, Kiel, Germany, ²Lund University, Skåne University Hospital, Lund, Sweden, ³Rheumatology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, ⁴Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶Centre for Rheumatology Research, University Hospital Reykjavik, Reykjavik, Iceland
Background/Purpose: Since the publication of the 2016 European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of ANCA-associated vasculitis (AAV), the publication of…
Abstract Number: 0513 • ACR Convergence 2022
The Association Between Age of Diagnosis and Disease Characteristics and Damage in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Jessica Bloom¹, Kaci Pickett², Lori Silveira², David Cuthbertson³, Nader Khalidi⁴, Curry Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland¹, Christian Pagnoux⁹, Rennie Rhee¹⁰, Philip Seo¹¹, Ulrich Specks¹², Kenneth J. Warrington¹², Robert Fuhlbrigge¹ and Peter Merkel¹⁰, ¹University of Colorado, Denver, CO, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of South Florida, Tampa, FL, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Cleveland, OH, ⁷University of Pennsylvania, Philadelphia, ⁸VA Boston Healthcare System, Boston, MA, ⁹Mount Sinai Hospital, Toronto, ON, Canada, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, Rochester, MN
Background/Purpose: Clinical characteristics and outcomes often differ between children and adults diagnosed with the same rheumatic condition; however, such comparative data is limited in ANCA-associated…
Abstract Number: 0526 • ACR Convergence 2022
Characteristics and Outcomes of Participants with and Without Diffuse Alveolar Hemorrhage in the Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis (PEXIVAS) Trial
Lynn Fussner¹, Luis Felipe Flores-Suarez², Rodrigo Cartin-Ceba³, Ulrich Specks³, P. Gerard Cox⁴, David Jayne⁵, Peter Merkel⁶ and Michael Walsh⁴, ¹The Ohio State University, Columbus, OH, ²Instituto Nacional de Enfermedades Respiratorias, Ciudad de México, Mexico, ³Mayo Clinic, Rochester, MN, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening manifestation of ANCA-associated vasculitis (AAV). Studies describing patients with DAH in AAV have typically been small…
Abstract Number: 1072 • ACR Convergence 2022
Efficacy and Safety Assessment of a Rituximab Biosimilar in Patients with Granulomatosis with Polyangiitis (GPA)
Adil Vural¹, Komal Mushtaq¹, Chao Zhang¹, Mahmoud Alwakeel¹, Vickie Sayles¹, Kristine Duly², Carol Langford¹ and Rula Hajj-Ali³, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Fairview Park, OH, ³Cleveland Clinic, Hunting Valley, OH
Background/Purpose: A biosimilar is a medication that is highly similar to a biologic agent that is already approved by a regulatory organization. Considering the share…
Abstract Number: 1073 • ACR Convergence 2022
Analysis of Clinical Outcomes in ANCA-associated Vasculitis Treated with Rituximab: Eighty Years a Single Center Experience in Japan
Soko Kawashima¹, Mitsumasa Kishimoto², Yoshinori Komagata³ and Shinya kaname⁴, ¹Kyorin University, Mitaka Tokyo, Japan, ²Kyorin University School of Medicine, Yokohama, Japan, ³Kyorin University School of Medicine, Tokyo, Japan, ⁴Kyorin University, Tokyo, Japan
Background/Purpose: Contrary to many Western countries, MPO-ANCA-associated vasculitis (MPO-AAV) is dominant in Japan. The therapeutic response to rituximab (RTX) may differ. Therefore, we conducted a…
Abstract Number: 0418 • ACR Convergence 2021
Longitudinal Patterns of Renal Function in ANCA-Associated Vasculitis
Jennifer Hanberg¹, Xiaoqing Fu¹, Claire Cook², John Stone³, Hyon K. Choi⁴ and Zachary Wallace⁵, ¹Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Lexington, MA, ⁵Massachusetts General Hospital, Newton, MA
Background/Purpose: Renal involvement is common in ANCA-associated vasculitis (AAV). Prior analyses show that end stage renal disease (ESRD) in AAV may be multifactorial. Little is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].